The Technology Development Board (TDB) of the Department of Science & Technology announced on 12 October 2026 that it has signed an agreement to provide ₹86 crore in financial support to Peptris Technologies Private Limited. This funding, provided as Optionally Convertible Debt under the Research Development and Innovation (RDI) Fund, supports the VIGOR programme which has a total cost of ₹172 crore. The project aims to move four AI-discovered drug candidates for neuromuscular disorders, oncology, alopecia, neuropathy, and DMD from Technology Readiness Level 4 to Level 6. The development programme is planned to progress over three years.
Key points
- ₹86 crore provided by TDB via Optionally Convertible Debt
- Total project cost for VIGOR programme is ₹172 crore
- Targets advancement of 4 drug candidates from TRL-4 to TRL-6
- Project duration is planned over three years
- Focuses on neuromuscular disorders, oncology, alopecia, neuropathy, and DMD
When it applies
- Over three years development programme encompassing preclinical and IND-enabling studies
Who it affects
- private company